Abstract. Aberrant hypermethylation of the CpG islands in the promoter region plays a casual role in the inactivation of various key genes involved in the cell cycle regulatory cascade, which could result in loss of cell cycle control. The aim of the present study was to investigate the role of promoter methylation of genes with a proven involvement in the cell cycle regulation of malignant astrocytomas. We profiled the CpG island methylation status of the RB1, p14
Introduction
Malignant astrocytoma [grade 3 anaplastic astrocytoma (AA) and grade 4 glioblastoma multiforme (GBM)] is the most frequent and malignant neoplasm of the human nervous system. Despite optimal treatment by cytoreductive surgery, radiation therapy, and chemotherapy, the prognosis remains dismal: The median survival of patients with GBM is approximately 1 year. Over the past decade, our understanding of the molecular genetic abnormalities involved in the pathogenesis and progression of malignant astrocytomas has advanced significantly. The most common alterations in these tumors include somatic mutation of the p53 and PTEN genes, homozygous deletion of the p14 ARF , p15 INK4b , and p16
INK4a
genes, and amplification of the cyclin-dependent kinase 4 (CDK4), MDM2, and EGFR genes (1-3). Disruption of cell cycle regulation plays an important role in the carcinogenic process. One of the major checkpoints controlling cell cycle progression from the G1 to S phase involves the retinoblastoma (RB1)/CDK4/p16
INK4a /p15
INK4b pathway. The p16 INK4a and p15 INK4b proteins inhibit the CDK4-and CDK6-mediated phosphorylation of the RB1 protein and thereby negatively regulate cell proliferation by mediating cell cycle arrest at the G1 phase (4, 5) . The p53/p14 ARF /MDM2 pathway also plays a crucial role in cell cycle regulation. Following DNA damage, p53 is activated and induces the transcription of a large number of genes including p21
Waf1/Cip1 , which is capable of silencing the CDKs that are essential for progression through the G1 and S phases of the cell cycle (6) . The p14 ARF protein inhibits the MDM2-mediated degradation of p53 and thus increases the ability of p53 to induce cell cycle arrest, apoptosis, and DNA repair (7) (8) (9) (10) . It has become apparent that many of the genetic alterations frequently detected in malignant astrocytomas affect the genes that encode members of these two critical regulatory pathways (1) (2) (3) .
Aberrant hypermethylation of the CpG islands in the promoter region has emerged as a critical alternative mechanism for the epigenetic inactivation of tumor suppressor genes in cancer development. Several members of the cell cycle regulatory gene family, including RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73, are occasionally subject to regulation of methylation at the transcriptional level in a variety of human tumors (11) (12) (13) . Particularly in a subset of hematological malignancies, the presence of methylation of critical regulatory genes such as p15 INK4b and p21 Waf1/Cip1 has been found to be of value in predicting poor prognosis (14, 15) . In diffuse gliomas, some of these regulatory genes have evidently been affected by aberrant hypermethylation (16) (17) (18) (19) (20) (21) (22) . However, no study has so far been conducted that focuses on the comprehensive methylation profile of the key cell cycle regulatory genes in malignant astrocytomas.
The aim of the present study was to investigate extensively the prevalence and role of promoter methylation of the cell cycle regulation-associated genes in malignant astrocytomas. We examined the methylation profiles of 7 cell cycle regulatory genes (RB1, p14
Waf1/Cip1 , p27 Kip1 , and p73) in a homogeneous cohort of patients with malignant astrocytomas, and assessed the contribution of these abnormalities to their clinical behavior.
Patients and methods
Patient population. Between April 1991 and December 2001, a total of 62 patients with a new histological diagnosis of supratentorial AA (grade III) and GBM (grade IV) classified according to the World Health Organization criteria (23) were included in a prospective study designed to evaluate the efficacy of human fibroblast interferon natural beta type, 1 -(4-amino-2-methyl-5-pyrimidinyl)methyl-3-2(2-chloroethyl)-3-nitrosourea (ACNU), and radiation therapy (termed IAR therapy) as reported previously (24) . Patients who were <18 years of age at the time of operation were excluded from the present study. All cases demonstrated contrast-enhancement on T1-weighted magnetic resonance imaging (MRI) at the preoperative examination. Among the 62 malignant astrocytomas, 54 tumor samples were available for methylation analysis, and these constituted the study population. The study protocol was approved by the Clinical Research Ethics Committee, and all patients gave informed consent for the genetic analyses to be undertaken.
Postoperative MRI scans with contrast were performed within 72 h of the operation. Regarding the extent of surgery, the absence of contrast-enhancement on postoperative T1-weighted MRI was defined as radical surgery; the presence of remnant enhancement was defined as palliative surgery. A radiographic response was defined as a decrease in tumor size of ≥50% as assessed by comparing the immediate postoperative MRI scans with follow-up scans obtained on the same MRI scanner, employing standard cross-sectional diameter measurements of the enhancing tumor, as reported previously (24) .
Methylation-specific polymerase chain reaction (PCR).
Genomic DNA was extracted from paraffin sections as described previously. Promoter hypermethylation of the RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73 genes was determined by the methylation-specific PCR (25) . Sodium bisulfite modification was performed with a CpGenome™ DNA modification kit (Intergen, Oxford, UK) as described previously (17, 19) . The methods used for methylation-specific PCR of the RB1, p14 ARF , p15 INK4b , p16 INK4a , and p73 genes were as described previously (17, (19) (20) (21) (22) 26 Kip1 methylated and unmethylated reactions) for 30 sec, and extension at 72˚C for 1 min. A final extension step at 72˚C for 5 min was added. The amplified products were electrophoresed on 3% agarose gels, and were visualized with ethidium bromide. CpGenome Universal Methylated DNA (Intergen) and normal blood DNA were included in each PCR set as the methylated and unmethylated controls, respectively.
Immunohistochemistry. Staining for the p73 protein was performed using the polyclonal antibody p73 (Ab6, Neomarkers; Lab Vision Corporation, Fremont, CA, USA). The sections were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was blocked by incubation with 0.3% hydrogen peroxidase in methanol for 30 min at room temperature. After deparaffinization and rehydration, the sections were immersed in 0.01 M citrate buffer (pH 6.0) and heated in a microwave oven. They were then incubated overnight at 4˚C with an anti-p73 antibody (1:50 dilution). The reaction was visualized using a Vectastain ABC kit and diaminobenzidine (Vector Laboratories, Burlingame, CA, USA). The percentage of nuclear positivity for p73 staining per 100 tumor cells was determined in 10 randomly chosen fields, and the average was calculated.
Statistical analysis. The Kaplan-Meier method was employed to calculate the progression-free survival (PFS) and overall survival (OS). We designated the PFS as the time period from the start of IAR therapy to the point when radiographic evidence of progressive disease was noted. When progressive disease was evident at the time of the first evaluation, the PFS was set at zero. The OS was defined as the interval between the start of IAR therapy and the date of death or the most recent evaluation. The log-rank test was used to assess the degree of significance of the differences in the different subgroups. The Cox proportional hazards model was employed to identify the multivariate predictors of survival. When a potential prognostic factor was judged to be independent and appropriate for the model, the relative risk (RR) and 95% confidence interval (CI) were calculated. The relationships between the various parameters were analyzed statistically using the Chi-square test, Fisher's exact test, or the Mann-Whitney U test as appropriate. The significance level chosen was P<0.05, and all tests were two-sided. The statistics were analyzed with a personal computer using Stat View J-5.0 software (Abacus Concepts, Berkeley, CA).
Results
Patient characteristics. The patients comprised of 30 men and 24 women aged 19 to 83 years (median, 53 years). The histological diagnosis was AA in 23 patients and GBM in 31 patients. Cytoreductive surgery was performed in all 54 patients. Radical resection was accomplished in 25 patients (46%), while 29 patients (54%) underwent palliative surgery. Of the 29 patients who had radiographically measurable disease on immediate MRI scans, 9 patients (31%) responded to IAR therapy.
At the end point of observation (January 2005), 10 patients were alive without disease, 3 were alive with disease, and 41 were dead of the disease. Among the 13 survivors, the duration of follow-up evaluations (from the onset of IAR therapy) ranged from 40 to 136 months with a median of 65 months.
Methylation analysis. Among all 54 tumors investigated, promoter hypermethylation of the RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73 genes was detected in 3 (6%), 7 (13%), 4 (7%), 2 (4%), 1 (2%), 3 (6%), and 12 samples (22%), respectively (Fig. 1) . The patterns of these abnormalities in the individual tumors were then compared. Waf1/Cip1 , one case for p27 Kip1 and p73, and one case for RB1 and p73. None of the tumors had three or more methylated loci. When all of the abmormalities were combined, 27 of the 54 tumors (50%) displayed aberrant methylation of at least one of the cell cycle regulatory genes tested.
The characteristics of the patients according to their methylation status are summarized in Table I . The MIB-1 staining had been examined previously (27) . No methylation status, either alone or in combination, was associated significantly with the clinicopathological parameters including age, sex, Karnofsky performance scale (KPS), histological type, response to IAR therapy, and MIB-1 labeling index (P>0.05 for each comparison).
Immunohistochemistry for p73. The p73 gene was the most prevalently methylated gene in our cohort of patients. This prompted us to investigate the expression level of the p73 protein in malignant astrocytomas by immunohistochemical assay. Due to the limitations in the amount of paraffinembedded tissues, only 40 tumor samples were available for immunohistochemical examination of their p73 protein expression (Fig. 2) . The percentage of immunoreactive tumor cells ranged widely from 0.01 to 50.6% (mean, 3.86±9.14%; Survival analysis. For the entire study population, the median PFS was 11 months with 1-, 2-, and 5-year PFS rates of 50%, 33%, and 22%, respectively. The estimated median OS was 16 months with 1-, 2-, and 5-year OS rates of 63%, 44%, and 27%, respectively. The results of univariate statistical analysis of the variables affecting the PFS and OS in a total of 53 patients are summarized in Table II . No methylation status, alone or in combination, was associated with either the PFS or OS. Also, the immuhistochemical p73 expression had no statistically significant effect on survival. In contrast, age, histological grade, KPS, and the extent of surgery influenced both the PFS and OS significantly. We next analyzed the AA and GBM patients separately. None of the methylation markers was correlated with either the PFS or OS in each subgroup; however, the sizes of the subsets were too small to draw any firm conclusions (data not shown).
Discussion
In the present study, we determined the methylation status of a series of well-characterized cell cycle regulation genes (RB1, p14 ARF , p15 INK4b , p16 INK4a , p21 Waf1/Cip1 , p27 Kip1 , and p73) Table I . Characteristics of 54 patients with malignant astrocytomas according to the methylation status of the p14 ARF and p73 genes and the methylation patterns of 7 cell cycle regulatory genes.
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-----------------------------------------------------------------------------------------------------a The methylation status of the RB1, p15
INK4b , p16 INK4a , p21 Waf1/Cip1 , or p27 Kip1 gene alone was not applicable for statistical analysis, due to the limited numbers of each methylation; b at least one methylation of the 7 cell cycle regulatory genes tested; c twenty-five patients were not assessable for their response to adjuvant therapy; d the MIB-1 staining was examined previously (26) ; KPS, Karnofsky performance scale; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme; IAR, interferon-ß, 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-2(2-chloroethyl)-3-nitrosourea (ACNU), and radiation therapy; LI, labeling index.
in 54 malignant astrocytomas. The results demonstrated that aberrant methylation of at least one CpG island is a common event (50%) in our tumor series, although the genes rarely hypermethylated (<13%, except p73 at 22%). These loci were unlikely to be methylated concurrently with other genes, suggesting that the epigenetic silencing of these genes may have similar effects on cell cycle deregulation. We further provide evidence that no methylation status, alone or in combination, was significantly correlated with the clinicopathological parameters tested, including tumor grade, proliferation activity, and patient survival. Coupled with data provided by us in a previous investigation of diffuse astrocytomas demonstrating hypermethylation of several cell cycle regulatory genes already in low-grade forms (22) , these findings suggest that the aberrant promoter methylation of the key cell cycle-related genes may occur at an early stage in the formation of diffusely infiltrating astrocytomas.
The p73 gene encodes the p73 protein highly homologous to p53 in three regions, corresponding to the p53 transcription domain, the DNA-binding domain, and the ONCOLOGY REPORTS 16: 957-963, 2006 Table II. Univariate analysis of the association of factors with the PFS and OS in a total of 54 patients with malignant astrocytomas. 
At least one status of methylation of the 7 cell cycle regulatory genes was tested; b fourteen tumor samples were not available for immunohistochemical examination; PFS, progression-free survival; OS, overall survival; KPS, Karnofsky performance score; AA, anaplastic astrocytoma; GBM, glioblastoma multiforme. (28) . It maps to chromosome 1p36.3, a region that is deleted in approximately 10-20% of malignant astrocytomas (21) . While mutations or homozygous deletions are either absent or extremely rare, it has been suggested that p73 may be an imprinted and monoallelically expressed gene, which could be inactivated by a single event affecting the normally expressed allele (28) . In support of its role as a tumor suppressor function, hypermethylation of the CpG island of the promoter and the untranslated exon 1 has been demonstrated to be associated with its inactivation in a variety of human neoplasms including diffuse gliomas (21, (28) (29) (30) . In our cohort of patients, p73 represented the most frequently methylated gene (22%), showing a frequency similar to that observed in a previous study (21) . To our knowledge, the present investigation is the first to evaluate the possible prognostic impact of p73 alteration in diffuse gliomas. We found no correlation between p73 hypermethylation and clinical outcomes, therefore arguing against a diagnostic utility for the methylation analysis of this gene.
In addition to the fact that the p73 gene has a monoallelic or biallelic expression in different tissue types, several lines of evidence indicating p73 protein accumulation or increased p73 transcript expression in various tumor samples over corresponding normal tissues through monoallelic induction of the transcriptionally active allele and/or activation of the normally silent allele, make it difficult to understand the role of this gene in cancer development (31) (32) (33) (34) . Two different isoforms have been identified: Full-length TAp73 generated from the P1 promoter, and the NH 2 -terminally truncated ¢Np73 derived from the alternative P2 promoter located in intron 3 (35) . In the cellular response to a subset of DNA damage including those induced by radiation and chemotherapeutic agents, the TAp73 transactivates a large number of p53-responsive genes such as p21 Waf1/Cip1 , and induces cell cycle arrest and apoptosis in a p53-independent manner (36, 37) . In a study by Liu et al (38) , p73 overexpression detected by immunohistochemistry, which may well reflect an accumulation of TAp73 isoforms, was found to serve as an indicator of higher radiosensitivity and better survival in patients with cervical cancers. In contrast, the ¢Np73 exhibits a dominant-negative behavior towards the TAp73 as well as the wild-type p53, and prevents the induction of cell growth arrest and apoptosis in tumor cells, thereby participating in oncogenesis (37) . Consistent with this notion, the positive expression of ¢Np73 is closely associated with a poor prognosis in neuroblastomas and lung cancers (39, 40) . Concerning diffuse gliomas, p73 transcript expression is low or undetectable in low-grade astrocytomas, whereas a large proportion of ependymomas and high-grade gliomas display an increased expression of the p73 transcript (41) (42) (43) , which reportedly is due to the up-regulation of TAp73 rather than ¢Np73 (43) . Since E2F directly regulates p73 by binding to E2F-binding sites within the TAp73 promoter, an enhanced p73 expression could be interpreted as an activation of E2F transcription factors resulting from a loss of RB1 function (43) . In the present study using the polyclonal antibody p73 raised against TAp73 isoforms, expression of the p73 protein was not associated with any distinct clinical characteristics such as responsiveness to adjuvant therapy and prognosis, although the small number of tumors did not permit any firm conclusions to be made about such correlations. p21 Waf1/Cip1 and p27 Kip1 represent the Kip/Cip family of CDK inhibitors that regulates the progression from the G1 into the S phase by inhibiting a variety of CDKs. While a loss of p21
Waf1/Cip1 or p27 Kip1 expression has been observed in a significant proportion of malignant astrocytomas, only p27 Kip1 had a predictive value for patients with these tumors (44, 45) . In vitro, p27
Kip1 exhibits a higher ability to suppress the growth of glioma cells than do the other CDK inhibitors including p14 ARF , p16 INK4a , and p21 Waf1/Cip1 , suggesting that p27 Kip1 has the most potent tumor suppressor role in diffuse gliomas (46) . In the present study, the p27 Kip1 gene was methylated in 4 (7%) of the 54 samples, with no significant association with any of the clinicopathological parameters. Although we were unable to assess the expression level of p27
Kip1 because of the limitations in the amount of paraffinembedded tissues, our finding of a low frequency of p27 Kip1 hypermethylation implies that aberrant methylation may represent a minor mechanism responsible for the disruption of p27
Kip1 function. It seems that the regulation of p27
Kip1 occurs primarily at the post-translational level though the ubiquitin proteosome-mediated degradation system (47).
In conclusion, a considerable proportion (50%) of malignant astrocytomas carried aberrant methylation of at least one locus of the key cell cycle regulatory genes, although each gene hypermethylation was found in only a small fraction, with no association with any of the clinicopathological parameters. Our observations suggest a minimal role for the epigenetic silencing of these regulatory genes in the pathogenesis of malignant astrocytomas.
